Special Arrangements Examinations
ACADEMIC YEAR 2023–2024
It is hereby announced that, following the decision of the Assembly of the Department of Visual Arts of the Athens School of Fine Arts (ASFA) on 10 July 2023, and given the specific nature of the School’s subject area -unlike other higher education institutions, it requires particular artistic aptitude from prospective students- those falling under the category of special provisions, in accordance with decision no. Φ.153/104779/Α5 (Government Gazette 2416/25.6.2018, Series B), may be admitted under a quota that corresponds to 5% of the total number of incoming students.
Candidates who fall under the above special category must:
(a) Submit a portfolio including up to 15 pieces of related work (black-and-white and colour drawings, etc.),
(b) Attend drawing examinations based on plaster casts or live models — or create tactile works using various materials in the case of candidates who are blind or have low vision.
The examinations will be held over two days, four (4) hours per day (from 8:30 a.m. to 12:30 p.m.), from Monday 4 December 2023 to Tuesday 5 December 2023.
Candidates will be asked to produce black-and-white drawings — or tactile works made from various materials for candidates who are blind or visually impaired — based on a plaster cast or a live model. In the case of justified absence on the above dates (due to illness), the examination period may be extended for two more days during the same hours.
From the total number of works produced during the examinations, each candidate selects and submits one (1) to two (2) drawings from the plaster cast section.
The works produced during the exams will not be returned. Only the initial portfolio submitted for participation in the examinations will be returned.
The required materials (e.g., pencil, charcoal or ink — or tactile materials for blind or visually impaired candidates) must be brought by the candidate.
Drawing boards and paper will be provided by the School.
The Seven-Member Examination Committee, taking into account the special conditions, will evaluate the submitted portfolio and the works produced during the exams.
Candidates eligible under the special provisions category include individuals with the following conditions:
| CODE | DISABILITY |
| 01 | REVOKED – merged with code 02 |
| 02 | Visual impairment with a disability rate of at least 67% |
| 03 | Bilateral hearing loss with a disability rate of at least 67% |
| 04 | Deaf-mute individuals |
| 05 | Congenital haemolytic anaemias requiring transfusions or with serious clinical manifestations corresponding to a disability rate of 67% or more |
| 06 | Congenital hydrocephalus |
| 07 | Duchenne muscular dystrophy or nemaline myopathy |
| 08 | Severe vascular malformation of the brainstem |
| 09 | Individuals currently suffering from or with a history of malignant neoplasms (leukaemia, lymphoma, solid tumours) |
| 10 | Budd-Chiari syndrome |
| 11 | Fabry disease |
| 12 | Cystic fibrosis of the pancreas and lungs |
| 13 | Multiple sclerosis |
| 14 | Severe myasthenia gravis under major immunosuppressive treatment |
| 15 | Kidney diseases requiring haemodialysis or peritoneal dialysis |
| 16 | Congenital bleeding disorders – haemophilia with chronic replacement therapy using clotting factors |
| 17 | Individuals who have undergone transplants: bone marrow |
| 18 | Individuals who have undergone transplants: cornea |
| 19 | Individuals who have undergone transplants: heart |
| 20 | Individuals who have undergone transplants: liver |
| 21 | Individuals who have undergone transplants: lungs |
| 22 | Individuals who have undergone transplants: kindey |
| 23 | Individuals who have undergone transplants: pancreas |
| 24 | Individuals who have undergone transplants: small intestin |
| 25 | Type 1 insulin-dependent juvenile diabetes or MODY type insulin-treated diabetes under the age of 20 |
| 26 | REVOKED – merged with code 52 |
| 27 | Motor disabilities with a disability rate of at least 67% |
| 28 | Phenylketonuria |
| 29 | Congenital thrombophilia under lifelong anticoagulant therapy |
| 30 | Arrhythmogenic right ventricular dysplasia with implanted defibrillator |
| 31 | Gaucher disease |
| 32 | Complex congenital heart conditions, operated or unoperated |
| 33 | Hypertrophic cardiomyopathy |
| 34 | Pulmonary arterial hypertension confirmed by right heart catheterisation |
| 35 | Severe pulmonary fibrosis of any cause |
| 36 | Idiopathic ventricular tachycardia with implanted defibrillator | |
| 37 | Glycogen storage diseases | |
| 38 | Cirrhosis of the liver with portal hypertension | |
| 39 | REVOKED – merged with code 38 | |
| 40 | Crohn’s disease or ulcerative colitis under biological or targeted therapy | |
| 41 | Wilson’s disease | |
| 42 | Neurofibromatosis (Recklinghausen syndrome) with systemic involvement | |
| 43 | Multiple myeloma | |
| 44 | Sarcoidosis under or previously treated with major immunosuppressants and continuing with relevant medication due to lung or CNS involvement | |
| 45 | Autoimmune hepatitis under or previously treated with major immunosuppressants and continuing with relevant medication | |
| 46 | Total laryngectomy | |
| 47 | Craniopharyngioma of the brain | |
| 48 | Systemic lupus erythematosus under or previously treated with major immunosuppressants and continuing with relevant medication due to kidney and/or CNS and/or serous membranes and/or blood involvement | |
| 49 | Systemic scleroderma with diffuse skin involvement | |
| 50 | REVOKED – merged with code 40 | |
| 51 | Ulcerative colitis with total proctocolectomy and permanent ileostomy or subtotal colectomy with ileoanal anastomosis | |
| 52 | Autoimmune haemolytic anaemia or autoimmune thrombocytopenia under major immunosuppressive therapy | |
| 53 | Klippel-Feil syndrome | |
| 54 | Juvenile idiopathic arthritis under biological therapy | |
| 55 | REVOKED – merged with code 80 | |
| 56 | Paroxysmal nocturnal haemoglobinuria requiring chronic transfusions | |
| 57 | Individuals with rare congenital, hereditary or acquired syndromes/diseases with disability percentage at least 67% | |
| 58 | Klippel-Trenaunay-Weber syndrome | |
| 59 | Mucopolysaccharidosis type 6 | |
| 60 | Individuals with dermatomyositis receiving major immunosuppressive therapy or previously treated with major immunosuppressive therapy and continuing with different but related medication for the disease | |
| 61 | Individuals with autoinflammatory syndromes, such as cryopyrinopathies (CAPS) (CINCA, FCAS and Muckle-Wells syndrome), TRAPS (TNF-Receptor Associated Periodic Syndrome), HIDS (Hyper IgD Syndrome/Mevalonate Kinase Deficiency), DIRA (Deficiency of IL-1 Receptor Antagonist) and familial Mediterranean fever under treatment with biological agents | |
| 62 | Individuals with severe hereditary angioedema | |
| 63 | Individuals with benign brainstem tumor with disability percentage at least 67% | |
| 64 | Individuals with ruptured aneurysm with hemorrhage and hydrocephalus with disability percentage at least 67% | |
| 65 | Individuals with dyserythropoietic anemia documented with long-term need for transfusions | |
| 66 | Tuberous sclerosis or Bourneville disease | |
| 67 | Marfan syndrome | |
| 68 | Crouzon syndrome or craniofacial dysostosis | |
| 69 | Melorheostosis with disability percentage at least 67% | |
| 70 | Ichthyosiform erythroderma with disability percentage at least 67% | |
| 71 | Epilepsy with disability percentage at least 67% | |
| 72 | Systemic mastocytosis under treatment | |
| 73 | Kawasaki disease with coronary disease or giant coronary aneurysms | |
| 74 | Ichthyosis foliaris | |
| 75 | Short bowel syndrome | |
| 76 | Idiopathic nephrotic syndrome under major immunosuppressive therapy | |
| 77 | Individuals with vasculitis under biological or major immunosuppressive therapy or previously treated and continuing with different but related medication for the disease | |
| 78 | Individuals with severe congenital immunodeficiency under replacement therapy with immunoglobulins | |
| 79 | Glomerulonephritis under major immunosuppressive therapy | |
| 80 | Acquired immunodeficiency syndrome (HIV stage C) under antiretroviral therapy with severity level 3 | |
| 81 | Takayasu vasculitis under biological or major immunosuppressive therapy | |
| 82 | Aplastic anemia | |
| 83 | Ornithine transcarbamylase enzyme deficiency | |
| 84 | Spinal muscular atrophy (SMA) with disability percentage at least 67% | |
| 85 | Systemic Langerhans cell histiocytosis | |
| 86 | Guillain-Barré neurological syndrome with disability percentage at least 67% | |
| 87 | Ischemic stroke with disability percentage at least 67% | |
| 88 | Catecholaminergic polymorphic ventricular tachycardia | |
| 89 | Ladd syndrome | |
| 90 | Progressive familial intrahepatic cholestasis type 3 (PFIC3) | |
| 91 | Diffuse developmental disorder with disability percentage at least 67% | |
| 92 | Ankylosing or psoriatic spondyloarthritis under biological or targeted therapy with disability percentage at least 67% | |
| 93 | Congenital adrenal hyperplasia | |
| 94 | Idiopathic myoclonic epilepsy with disability percentage at least 67% | |
| 95 | Cerebral palsy type right spastic hemiplegia with disability percentage at least 67% | |
| 96 | Cerebral palsy with disability percentage at least 67% | |
| 97 | Spontaneous intracranial hypotension, Chiari syndrome type I with disability percentage at least 67% | |
| 98 | Ollier disease with disability percentage at least 67% | |
| 99 | Hypophosphatemic rickets | |
| 100 | Chronic sensory-motor axonal polyneuropathy with disability percentage at least 67% | |
| 101 | Primary myocardial tumors | |
| 102 | Individuals with severe complex congenital heart diseases including: A) pulmonary vascular disease and pulmonary hypertension including Eisenmenger syndrome B) cyanotic congenital heart diseases C) double outlet right ventricle D) Fontan or Fontan-type circulation E) interrupted aortic arch F) pulmonary artery atresia G) systemic right ventricle H) single ventricle I) arterial trunk J) complex anomalies of atrioventricular or ventriculoarterial connection | |
| 103 | Individuals with moderate complex or other congenital heart diseases provided that: A) they have an implantable cardioverter defibrillator B) they receive treatment for heart failure C) they had increased biomarkers (BNP, NT-pro BNP) before treatment | |
| 104 | Cardiomyopathies with low ejection fraction equal to or less than 40% | |
| 105 | Ebstein anomaly with heart failure | |
Important Note on Document Submission:
All documents and applications described below must be sent ONLY by postal mail with postmark or courier from Monday, November 6, 2023, until Tuesday, November 21, 2023 to the address:
“Athens School of Fine Arts, School of Fine Arts, Department of Visual Arts, Patission 42, 106 82 Athens.”
It is noted that any earlier or later date will be considered late and not accepted.
- Application
- A copy of the high school diploma or equivalent from a six-year, seven-year, or eight-year Secondary School, or an officially recognised equivalent qualification from Greece or abroad.
- A medical certificate confirming the disability, issued by the Seven-Member Committees for the certification of disabilities for admission to Higher Education. These committees are established at specific Public or University Hospitals, as defined by ministerial decisions.
- A photocopy of the ID card.
- Two (2) passport-size photos.